JP2019526262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526262A5 JP2019526262A5 JP2019512264A JP2019512264A JP2019526262A5 JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5 JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019512264 A JP2019512264 A JP 2019512264A JP 2019526262 A5 JP2019526262 A5 JP 2019526262A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- recombinant
- lab
- pharmaceutical composition
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710005285 RPL30 Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 230000003248 secreting Effects 0.000 claims description 16
- 210000004369 Blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 108060003233 epd Proteins 0.000 claims description 14
- 229920001204 Intergenic region Polymers 0.000 claims description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 11
- 101700075180 USP45 Proteins 0.000 claims description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 8
- 101710027742 SAS1019 Proteins 0.000 claims description 7
- 108010011224 trehalose-6-phosphate phosphorylase Proteins 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 102000037240 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 101700048841 trePP Proteins 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 108020003272 trehalose-phosphatase Proteins 0.000 claims description 4
- 101710037290 A674R Proteins 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
- 101700026084 THY1 Proteins 0.000 claims description 3
- 101710013732 TYMS Proteins 0.000 claims description 3
- 102000004965 antibodies Human genes 0.000 claims description 3
- 108090001123 antibodies Proteins 0.000 claims description 3
- 101700041358 thy Proteins 0.000 claims description 3
- 101710004584 thyA1 Proteins 0.000 claims description 3
- 229940076144 Interleukin-10 Drugs 0.000 claims description 2
- 210000004153 Islets of Langerhans Anatomy 0.000 claims description 2
- 108010076181 Proinsulin Proteins 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 6
- 210000000349 Chromosomes Anatomy 0.000 claims 5
- 102000003852 Autoantibodies Human genes 0.000 claims 3
- 108090000206 Autoantibodies Proteins 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102000008214 Glutamate decarboxylases Human genes 0.000 claims 2
- 108091022086 Glutamate decarboxylases Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulators Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 241000194035 Lactococcus lactis Species 0.000 claims 1
- 102100017349 PTPRN Human genes 0.000 claims 1
- 101700074964 PTPRN Proteins 0.000 claims 1
- 235000014897 Streptococcus lactis Nutrition 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 150000003147 proline derivatives Chemical class 0.000 claims 1
- 101710041304 pstI Proteins 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 101700064140 FOXP3 Proteins 0.000 description 67
- 238000002648 combination therapy Methods 0.000 description 54
- 210000004027 cells Anatomy 0.000 description 50
- 241000192129 Leuconostoc lactis Species 0.000 description 37
- 206010012601 Diabetes mellitus Diseases 0.000 description 29
- 101700082799 IL2RA Proteins 0.000 description 26
- 102100002950 ISG20 Human genes 0.000 description 26
- 101700015336 ISG20 Proteins 0.000 description 26
- 102100005310 CTLA4 Human genes 0.000 description 15
- 101700054183 CTLA4 Proteins 0.000 description 15
- 102100011133 GPSM2 Human genes 0.000 description 14
- 210000001744 T-Lymphocytes Anatomy 0.000 description 14
- 238000003780 insertion Methods 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 238000000692 Student's t-test Methods 0.000 description 12
- 102000016607 Diphtheria Toxin Human genes 0.000 description 11
- 108010053187 Diphtheria Toxin Proteins 0.000 description 11
- 101700068148 PINS Proteins 0.000 description 11
- 210000000496 Pancreas Anatomy 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 6
- 101700008889 otsB Proteins 0.000 description 5
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 4
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 101700083428 GPSM2 Proteins 0.000 description 3
- 210000001165 Lymph Nodes Anatomy 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 102000030951 Phosphotransferases Human genes 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 108060007869 BAH1 Proteins 0.000 description 2
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035533 AUC Effects 0.000 description 1
- 102100005832 CD69 Human genes 0.000 description 1
- 101700080416 CD69 Proteins 0.000 description 1
- 102100011855 FOXP3 Human genes 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 102100006425 GAPDH Human genes 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 108010067449 Thymidylate Synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001019 normoglycemic Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Description
Claims (21)
(a)前記hIL−10および前記hPINSを構成的に発現しかつ分泌し;
(b)トレハロース−6−リン酸ホスホリラーゼ(TrePP)活性を欠き;および
(c)セロビオース特異的PTS系IICコンポーネント(PtcC)活性を欠き;
および前記第1の外因性核酸が:
(i)配列番号2に対して少なくとも95%同一のヌクレオチド配列を含む;
(ii)hllAプロモーター(PhllA)によって転写調節される;および
(iii)前記組換えLABのthyA遺伝子座において染色体に組み込まれている;
からなる群から選択される少なくとも1つの特徴を有する、前記組換えLAB。 Containing two exogenous nucleic acids integrated into the chromosome , the first exogenous nucleic acid encodes human interleukin-10 ( hIL-10 ) and the second exogenous nucleic acid contains human proinsulin ( hPINS ) . A recombinant lactic acid bacterium (LAB) encoding , wherein the recombinant LAB is:
(A) Constitutively expresses and secretes the hIL-10 and the hPINS;
(B) Lack of trehalose-6-phosphate phosphorylase (TrePP) activity; and
(C) Lack of cellobiose-specific PTS-based IIC component (PtcC) activity;
And the first exogenous nucleic acid is:
(I) Containing at least 95% identical nucleotide sequence to SEQ ID NO: 2;
(Ii) Transcriptionally regulated by the hllA promoter (PhlA); and
(Iii) Integrated into the chromosome at the thyA locus of the recombinant LAB;
The recombinant LAB having at least one characteristic selected from the group consisting of .
a)Usp45分泌リーダー(SSusp45)を含む融合タンパク質として発現する;
b)成熟hIL−10の2位においてプロリン(Pro)からアラニン(Ala)への置換を含む;および
c)配列番号1に対して少なくとも95%同一のアミノ酸配列を含む;
からなる群から選択される少なくとも1つの特徴を有する、請求項1または2に記載の組換えLAB。 The hIL-10 is :
a) Expressed as a fusion protein containing the Usp45 secretory leader (SSsup45);
b) Including the substitution of proline (Pro) for alanine (Ala) at the 2-position of mature hIL-10 ; and
c) Contains at least 95% identical amino acid sequence to SEQ ID NO: 1;
The recombinant LAB of claim 1 or 2 , having at least one characteristic selected from the group consisting of .
a)配列番号4に対して少なくとも95%同一のヌクレオチド配列を含む;および
b)gapBプロモーター、gapB遺伝子、Usp45分泌リーダー(SSusp45)をコードする核酸配列、および第2の外因性核酸を5’から3’の順に含む第1のポリシストロン性発現カセットに挿入され、前記第1のポリシストロン性発現カセットが、Usp45分泌リーダー(SSusp45)を含むhPINS融合タンパク質を発現する;
からなる群から選択される少なくとも1つの特徴を有する、請求項1〜3のいずれか1項に記載の組換えLAB。 The second exogenous nucleic acid is:
a) Contains at least 95% identical nucleotide sequence to SEQ ID NO: 4 ;
b) The gapB promoter, the gapB gene, the nucleic acid sequence encoding the Upp45 secretory leader (SSsup45) , and the second exogenous nucleic acid are inserted into a first polycistron expression cassette containing 5'to 3'in the order described above. One polycistron expression cassette expresses the hPINS fusion protein containing the Upp45 secretory leader (SSsup45);
The recombinant LAB according to any one of claims 1 to 3 , which has at least one characteristic selected from the group consisting of .
a)配列番号3に対して少なくとも95%同一のアミノ酸配列を含む;およびa) Contains at least 95% identical amino acid sequence to SEQ ID NO: 3;
b)Usp45分泌リーダー(SSusp45)を含む融合タンパク質として発現される;b) Expressed as a fusion protein containing the Usp45 secretory leader (SSsup45);
からなる群から選択される少なくとも1つの特徴を有する、請求項1〜5のいずれか1項に記載の組換えLAB。The recombinant LAB according to any one of claims 1 to 5, which has at least one characteristic selected from the group consisting of.
a)外因性のトレハロース−6−リン酸ホスファターゼを発現する;および
b)少なくとも1つのトレハローストランスポーターをコードする遺伝子を構成的に過剰発現する;
からなる群から選択される少なくとも1つの特徴をさらに含む、請求項1〜6のいずれか1項に記載の組換えLAB。 The recombinant LAB:
a) Express exogenous trehalose-6-phosphate phosphatase ; and
b) constitutively overexpress the gene you encoding at least one trehalose transporter;
The recombinant LAB according to any one of claims 1 to 6 , further comprising at least one feature selected from the group consisting of .
前記少なくとも1つのトレハローストランスポーターが、ptsI遺伝子およびptsII遺伝子によりコードされ;
前記組換えLABが内因性の不活性化trePPを含むために、前記組換えLABがTrePP活性を欠き;および
前記組換えLABが内因性の不活性化ptcCを含むために、前記組換えLABがPtcC活性を欠く;
請求項7に記載の組換えLAB。 The trehalose-6-phosphate phosphatase is OtsB of Escherichia coli;
The at least one trehalose transporter is encoded by the ptsI and ptsII genes;
The recombinant LAB lacks TrePP activity because the recombinant LAB contains an endogenous inactivated trePP ; and
The recombinant LAB lacks PtcC activity because the recombinant LAB contains an endogenous inactivated ptcC ;
The recombinant LAB according to claim 7 .
b)gapBプロモーター、gapB遺伝子、Usp45分泌リーダー(SSusp45)をコードする核酸配列および前記第2の外因性核酸を5’から3’の順に含み、前記hPINSが前記SSusp45を含む融合タンパク質として発現する、染色体に組み込まれている第1のポリシストロン性発現カセット;
c)usp45プロモーター、usp45遺伝子、rpmD遺伝子のすぐ5’にある遺伝子間領域および大腸菌(Escherichia coli)のOtsBをコードする第3の外因性遺伝子を5’から3’の順に含む、染色体に組み込まれている第2のポリシストロン性発現カセット;
d)hllAプロモーター(PhllA)およびpstI遺伝子とpstII遺伝子を含む核酸を5’から3’の順に含む、第3のポリシストロン性発現カセット;
e)不活性化された内因性のtrePP遺伝子であって、前記trePP遺伝子は遺伝子の欠失により不活性化されることにより、前記組換えLABがTrePP活性を欠く、前記不活性化された内因性のtrePP遺伝子;および
f)不活性化された内因性のptcC遺伝子であって、前記ptcC遺伝子は未成熟終止コドンを挿入することによって不活性化されることにより、前記組換えLABがPtcC活性を欠く、前記不活性化された内因性のptcC遺伝子;
を含む、請求項2に記載の組換えLAB。 a) The recombinant in which the nucleic acid sequence encoding the Usp45 secretory leader ( SSsup45 ) and the hllA promoter (PhlLA) transcribing the first exogenous nucleic acid are included and the hIL-10 is expressed as a fusion protein containing the SSsup45. An expression cassette integrated into the chromosome at the LAB thyA locus ;
b ) The nucleic acid sequence encoding the gapB promoter, the gapB gene, the Upp45 secretory leader (SSsup45) and the second exogenous nucleic acid are contained in the order of 5'to 3', and the hPINS is expressed as a fusion protein containing the SSsup45. First polycistron expression cassette integrated into the chromosome ;
c) Integrate into the chromosome containing the usp45 promoter, the usp45 gene , the intergenic region immediately 5'of the rpmD gene and the third exogenous gene encoding OtsB of Escherichia coli in the order 5'to 3'. and it has a second polycistronic expression cassette;
d) A third polycistron expression cassette containing the hllA promoter (PhlA) and nucleic acids containing the pstI and pstII genes in the order 5'to 3' ;
e) An inactivated endogenous trePP gene in which the recombinant LAB lacks TrePP activity due to inactivation by deletion of the gene, the inactivated endogenous cause. Sexual trePP gene; and
f) An inactivated endogenous ptcC gene , wherein the recombinant LAB lacks PtcC activity by being inactivated by inserting an immature stop codon , said inactivity. Endogenous ptcC gene;
Including recombinant LAB according to claim 2.
a)前記T1D治療の転帰を予測するために、前記組換えLABまたは前記医薬組成物を投与する前に行われる;またはa) Performed prior to administration of the recombinant LAB or the pharmaceutical composition to predict the outcome of the T1D treatment; or
b)前記T1D治療の転帰をモニターし、測定するために、前記組換えLABまたは前記医薬組成物を投与した後に行われる;b) Performed after administration of the recombinant LAB or the pharmaceutical composition to monitor and measure the outcome of the T1D treatment;
請求項17に記載の医薬組成物。The pharmaceutical composition according to claim 17.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022010063A JP2022061035A (en) | 2016-09-02 | 2022-01-26 | Genetically modified bacterium that stably expresses il-10 and insulin |
JP2024009123A JP2024047590A (en) | 2016-09-02 | 2024-01-25 | Genetically engineered bacteria that stably express IL-10 and insulin |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383079P | 2016-09-02 | 2016-09-02 | |
US62/383,079 | 2016-09-02 | ||
PCT/IB2017/055287 WO2018042390A1 (en) | 2016-09-02 | 2017-09-02 | Genetically modified bacteria stably expressing il-10 and insulin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022010063A Division JP2022061035A (en) | 2016-09-02 | 2022-01-26 | Genetically modified bacterium that stably expresses il-10 and insulin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019526262A JP2019526262A (en) | 2019-09-19 |
JP2019526262A5 true JP2019526262A5 (en) | 2020-10-15 |
JP7016865B2 JP7016865B2 (en) | 2022-03-03 |
Family
ID=60120085
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512264A Active JP7016865B2 (en) | 2016-09-02 | 2017-09-02 | Gene-modified bacteria that stably express IL-10 and insulin |
JP2022010063A Pending JP2022061035A (en) | 2016-09-02 | 2022-01-26 | Genetically modified bacterium that stably expresses il-10 and insulin |
JP2024009123A Pending JP2024047590A (en) | 2016-09-02 | 2024-01-25 | Genetically engineered bacteria that stably express IL-10 and insulin |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022010063A Pending JP2022061035A (en) | 2016-09-02 | 2022-01-26 | Genetically modified bacterium that stably expresses il-10 and insulin |
JP2024009123A Pending JP2024047590A (en) | 2016-09-02 | 2024-01-25 | Genetically engineered bacteria that stably express IL-10 and insulin |
Country Status (8)
Country | Link |
---|---|
US (3) | US10858663B2 (en) |
EP (1) | EP3506932A1 (en) |
JP (3) | JP7016865B2 (en) |
CN (1) | CN109843320A (en) |
AU (1) | AU2017319707B2 (en) |
CA (1) | CA3035151A1 (en) |
RU (1) | RU2768027C2 (en) |
WO (1) | WO2018042390A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3512872A1 (en) | 2016-09-13 | 2019-07-24 | Intrexon Actobiotics NV | Mucoadhesive microorganism |
EP3897691A4 (en) * | 2018-12-21 | 2022-08-31 | The Regents of the University of California | Il-10-containing vaccines and uses thereof |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB227835A (en) | 1924-01-15 | 1925-04-09 | Harry Odell | Improvements in feeding mechanism for embossing and other printing presses |
US4919918A (en) | 1988-03-14 | 1990-04-24 | Spectrum Consumer Products Co., Inc. | Non-alcoholic mouthwash |
US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
GB9126306D0 (en) | 1991-12-11 | 1992-02-12 | Unilever Plc | Mouthwash compositions |
WO1993017117A1 (en) | 1992-02-27 | 1993-09-02 | Lynxvale Limited | Heterologous gene expression in lactococcus, and the expression products therefrom |
US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5700782A (en) | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
AU2149495A (en) | 1995-04-11 | 1996-10-30 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface |
US5695746A (en) | 1995-07-28 | 1997-12-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Liquid dentifrice with mouthwash fresh taste |
US6348187B1 (en) | 1996-01-24 | 2002-02-19 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
GB9611364D0 (en) | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
GB2318977B (en) | 1996-09-18 | 1999-07-21 | Erling Johansen | Compositions |
US5869118A (en) | 1996-11-13 | 1999-02-09 | Abbott Laboratories | Gellan gum to improve physical stability of liquid nutritional products |
US5897872A (en) | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
EP1383897B1 (en) | 2001-05-03 | 2006-06-28 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Self-containing lactococcus strain |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
EP1536749A2 (en) | 2002-07-08 | 2005-06-08 | Joe S. Wilkins, Jr. | Antibacterial formulations |
AU2003303222A1 (en) * | 2002-12-19 | 2004-07-14 | Universiteit Gent | Mutant proteins showing increased secretion |
JP5410759B2 (en) | 2005-11-29 | 2014-02-05 | アクトジェニックス・エヌブイ | Induction of mucosal tolerance to antigens |
CN101605900B (en) * | 2007-01-12 | 2014-04-23 | 阿克图杰尼斯公司 | Lactococcus promoters and uses thereof |
EP2774621B1 (en) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
MY146595A (en) * | 2007-03-28 | 2012-08-30 | Alimentary Health Ltd | Probiotic bifidobacterium strains |
JP5572972B2 (en) * | 2009-03-16 | 2014-08-20 | Jnc株式会社 | Screening method for drugs such as insulin secretagogues |
US9574169B2 (en) | 2009-04-30 | 2017-02-21 | Intrexon Actobiotics Nv | Cryoprotectants for freeze drying of lactic acid bacteria |
RU2766157C2 (en) | 2011-06-01 | 2022-02-08 | Интрексон Актобиотикс Н.В. | Polycistronic expression system for bacteria |
RU2653757C2 (en) | 2011-09-23 | 2018-05-14 | Интрексон Актобиотикс Н.В. | Modified gram positive bacteria and uses thereof |
-
2017
- 2017-09-02 JP JP2019512264A patent/JP7016865B2/en active Active
- 2017-09-02 EP EP17784999.9A patent/EP3506932A1/en active Pending
- 2017-09-02 US US16/329,321 patent/US10858663B2/en active Active
- 2017-09-02 CA CA3035151A patent/CA3035151A1/en active Pending
- 2017-09-02 RU RU2019104948A patent/RU2768027C2/en active
- 2017-09-02 WO PCT/IB2017/055287 patent/WO2018042390A1/en unknown
- 2017-09-02 CN CN201780054190.7A patent/CN109843320A/en active Pending
- 2017-09-02 AU AU2017319707A patent/AU2017319707B2/en active Active
-
2020
- 2020-11-09 US US17/092,624 patent/US11549118B2/en active Active
-
2022
- 2022-01-26 JP JP2022010063A patent/JP2022061035A/en active Pending
- 2022-11-29 US US18/059,689 patent/US20230348918A1/en active Pending
-
2024
- 2024-01-25 JP JP2024009123A patent/JP2024047590A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gagliani et al. | The fire within: microbes inflame tumors | |
Arnold et al. | Tolerance rather than immunity protects from Helicobacter pylori–induced gastric preneoplasia | |
Ma et al. | Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice | |
Heiseke et al. | CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell–mediated protection from colitis | |
JP2019526262A5 (en) | ||
JP2022023025A (en) | Composition and method for treating type 1 diabetes mellitus | |
Huss et al. | TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE | |
KR101291960B1 (en) | Controlled Production and Delivery of Biologically Active Agents by Gut Bacteria | |
CN113286615A (en) | Combination therapy of microorganisms and immunomodulators for the treatment of cancer | |
US9884098B2 (en) | Multivalent breast cancer vaccine | |
US20230348918A1 (en) | Genetically Modified Bacteria Stably Expressing IL-10 and Insulin | |
Roider et al. | Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer | |
TW201833323A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
US20080026986A1 (en) | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling | |
Torres et al. | IL-12p40/IL-10 producing preCD8α/Clec9A+ dendritic cells are induced in neonates upon Listeria monocytogenes infection | |
Cannon et al. | Cellular immunotherapy for ovarian cancer | |
WO2022086988A1 (en) | Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides | |
KR20220092523A (en) | Oncolytic viral vector encoding variant interleukin-2 (vIL-2) polypeptide | |
CN113056479A (en) | CD40 and CD40L conjugates in an adenoviral vaccine vehicle | |
CN116075526A (en) | Interleukin 2 fusion proteins and their use in IBD | |
AU2021367306A1 (en) | Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides | |
JP2023500563A (en) | Celiac disease treatment | |
Kong et al. | Expression of fusion IL2-B7. 1 (IgV+ C) and effects on T lymphocytes |